Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
复制标题
DOI：
10.1007/s11936-023-01024-0
复制
发表时间：
2023
影响因子：
--
通讯作者：
Zhu, Han
中科院分区：
文献类型：
--
作者：
Chan, Antonia;Torelli, Stefan;Cheng, Evaline;Batchelder, Ryan;Waliany, Sarah;Neal, Joel;Witteles, Ronald;Nguyen, Patricia;Cheng, Paul;Zhu, Han
尽管免疫检查点抑制剂(ICIS)改变了许多患者的寿命，但它们也可能引发长期心血管疾病的加速。我们的综述旨在考察ICI介导的动脉粥样硬化的研究现状，并解决关于其发病机制和对患者管理的影响的关键问题。临床前小鼠模型表明，T细胞失调和致动脉粥样硬化细胞因子的产生是检查点抑制后斑块形成的关键因素。临床数据也强调了动脉粥样硬化性心血管疾病(ASCVD)对免疫治疗患者的重大负担，尽管在这一人群中主动预防和治疗ASCVD的价值仍然是一个开放的研究领域。目前的治疗选择包括改变饮食/生活方式和传统药物来管理高血压、高脂血症和糖尿病风险因素；目前还没有针对性的治疗方法。早期识别高危患者对于有效的预防策略和及时干预至关重要。未来的研究应该集中在改进筛查工具，阐明导致ICI动脉粥样硬化的靶向机制，以及评估接受免疫治疗的癌症幸存者的长期心血管结果。此外，肿瘤学家和心脏病学家之间的密切合作对于优化患者预后至关重要。
Even as immune checkpoint inhibitors (ICIs) have transformed the lifespan of many patients, they may also trigger acceleration of long-term cardiovascular disease. Our review aims to examine the current landscape of research on ICI-mediated atherosclerosis and address key questions regarding its pathogenesis and impact on patient management. Preclinical mouse models suggest that T cell dysregulation and proatherogenic cytokine production are key contributors to plaque development after checkpoint inhibition. Clinical data also highlight the significant burden of atherosclerotic cardiovascular disease (ASCVD) in patients on immunotherapy, although the value of proactively preventing and treating ASCVD in this population remains an open area of inquiry. Current treatment options include dietary/lifestyle modification and traditional medications to manage hypertension, hyperlipidemia, and diabetes risk factors; no current targeted therapies exist. Early identification of high-risk patients is crucial for effective preventive strategies and timely intervention. Future research should focus on refining screening tools, elucidating targetable mechanisms driving ICI atherosclerosis, and evaluating long-term cardiovascular outcomes in cancer survivors who received immunotherapy. Moreover, close collaboration between oncologists and cardiologists is essential to optimize patient outcomes.
影响因子：
11.1
作者：
Barth, Sebastian Dietmar;Kaaks, Rudolf;Johnson, Theron;Katzke, Verena;Gellhaus, Katharina;Schulze, Janika Josephin;Olek, Sven;Kuehn, Tilman
通讯作者：
Kuehn, Tilman